Barclays Sticks to Their Buy Rating for Thermo Fisher (TMO)
Barclays analyst Luke Sergott maintained a Buy rating on Thermo Fisher today and set a price target of $625.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
According to TipRanks, Sergott is an analyst with an average return of -2.7% and a 36.77% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Certara, Thermo Fisher, and Sotera Health.
In addition to Barclays, Thermo Fisher also received a Buy from William Blair’s Matt Larew in a report issued today. However, on May 14, RBC Capital initiated coverage with a Hold rating on Thermo Fisher (NYSE: TMO).
Based on Thermo Fisher’s latest earnings release for the quarter ending March 28, the company reported a quarterly revenue of $11.01 billion and a net profit of $1.65 billion. In comparison, last year the company earned a revenue of $10.36 billion and had a net profit of $1.51 billion
Read More on TMO:
Disclaimer & DisclosureReport an Issue
- Thermo Fisher Scientific: Buy Rating Reaffirmed on Strengthening Organic Growth Outlook, Market Share Gains, and AI-Driven Demand Tailwinds
- Thermo Fisher highlights growth outlook, long-term value creation
- Thermo Fisher sees low-teens adjusted EPS growth over the long-term
- Amazon among seven added to Jefferies’ Franchise Picks list
- Thermo Fisher resumed with a Sector Perform at RBC Capital
